John C. Byrd
Impact in
- Genetics top 0.01%
- Chronic Lymphocytic Leukemia Research
- Hematology top 0.02%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
Papers in
- Genetics 504
- Chronic Lymphocytic Leukemia Research 486
- Hematology 228
- Acute Myeloid Leukemia Research 133
- Chronic Myeloid Leukemia Treatments 87
- Co-authors
- Amy Jo Johnson (121 shared papers)Jennifer Ann Woyach (117 shared papers)Michael R. Grever (114 shared papers)Nyla A. Heerema (70 shared papers)Joseph Michael Flynn (61 shared papers)Jeffrey Alan Jones (80 shared papers)Kristie A. Blum (48 shared papers)Thomas J. Kipps (36 shared papers)
- Journals
- Blood (294 papers)Leukemia (45 papers)Journal of Clinical Oncology (33 papers)Blood Advances (25 papers)Clinical Cancer Research (22 papers)
- Partner nations
- United StatesUnited KingdomItaly
In The Last Decade
John C. Byrd
717 papers receiving 51.3k citations
John C. Byrd's Hit Papers
Peers
Comparison fields: 5 of 181
- Genetics 24.5k
- Hematology 13.6k
- Pathology and Forensic Medicine 17.7k
- Immunology 11.7k
- Oncology 10.1k
Countries citing papers authored by John C. Byrd
This map shows the geographic impact of John C. Byrd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John C. Byrd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John C. Byrd more than expected).
Fields of papers citing papers by John C. Byrd
This network shows the impact of papers produced by John C. Byrd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John C. Byrd. The network helps show where John C. Byrd may publish in the future.
Co-authors
The 25 scholars most cited alongside John C. Byrd, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 731 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Hit paper breakdown → | 2000 | 8110 |
| 2 | Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Hit paper breakdown → | 2009 | 2165 |
| 3 | iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL Hit paper breakdown → | 2018 | 1254 |
| 4 | Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Hit paper breakdown → | 2014 | 1064 |
| 5 | Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia Hit paper breakdown → | 2001 | 883 |
| 6 | Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia Hit paper breakdown → | 2015 | 778 |
| 7 | The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody Hit paper breakdown → | 2010 | 712 |
| 8 | Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes Hit paper breakdown → | 2013 | 699 |
| 9 | Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 Hit paper breakdown → | 2011 | 681 |
| 10 | 2009 | 673 | |
| 11 | CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability Hit paper breakdown → | 2010 | 658 |
| 12 | Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. | 1998 | 587 |
| 13 | Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib Hit paper breakdown → | 2015 | 584 |
| 14 | Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib Hit paper breakdown → | 2017 | 553 |
| 15 | 2008 | 520 | |
| 16 | Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia Hit paper breakdown → | 2015 | 505 |
| 17 | 1995 | 495 | |
| 18 | Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial Hit paper breakdown → | 2021 | 485 |
| 19 | 2010 | 484 | |
| 20 | 2013 | 404 |
About John C. Byrd
John C. Byrd is a scholar working on Genetics, Hematology, Pathology and Forensic Medicine, Immunology and Oncology, having authored 731 papers that have together received 52.7k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (486 papers), Lymphoma Diagnosis and Treatment (227 papers), Acute Myeloid Leukemia Research (133 papers), Immunodeficiency and Autoimmune Disorders (106 papers), Chronic Myeloid Leukemia Treatments (87 papers), Acute Lymphoblastic Leukemia research (73 papers), Monoclonal and Polyclonal Antibodies Research (51 papers) and Advanced Breast Cancer Therapies (45 papers). The work is most often cited by research in Genetics (24.5k citations), Hematology (13.6k citations), Pathology and Forensic Medicine (17.7k citations), Immunology (11.7k citations) and Oncology (10.1k citations). John C. Byrd has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Amy Jo Johnson, Jennifer Ann Woyach, Michael R. Grever, Nyla A. Heerema, Joseph Michael Flynn, Jeffrey Alan Jones, Kristie A. Blum, Thomas J. Kipps, Natarajan Muthusamy and Thomas S. Lin. Their work appears in journals such as Blood, Leukemia, Journal of Clinical Oncology, Blood Advances and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.